ERBB2 and breast cancer: Since gene expression analysis is expensive and not universally feasible, several surrogate classifications based on immunohistochemistry and/or in situ hybridization standard techniques (estrogen receptor [ER], progesterone receptor [PR], Ki67, and HER2 expression) have been proposed [5–7] to guide BC treatment algorithms in clinical practice setting [8–10].